Hence, six combinations of tumour biomarkers along with the remaining predictors were considered in the analyses: (a) TNBC, (b) ER, (c) ER and HER2, (d) HR and HER2, (e) HER2, and (f) immune-histochemical subtypes. This evidence concerns the gene ERBB2 and neoplasm.